Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

NEW YORK (AP) — U.S. stocks climbed further into record heights on Thursday after a report showed the U.S. job market looks ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

A recent analysis of U.S. pharmacy claims shows that nearly two-thirds of patients who initiated treatment with the weight-loss drugs Wegovy or Zepbound remained on them a year later. The persistence ...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in early 2024 continued their treatment a year later. This marks a significant ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

Exclusive-New data show most US patients now stay on Wegovy, Zepbound after a year Stock Markets Published 06/25/2025, 06:08 AM Updated 06/25/2025, 11:26 AM ...